Hans Biomed

Hans Biomed FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Hans Biomed (042520.KQ) as of Nov 1, 2026 is 4.59 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 14.82 % — a change of -69.01% (lower).

FCF Conversion

4.59 %

YoY

-69.01%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Hans Biomed is 2025 4.59 % . FCF Conversion Rate (FCF/EBITDA) of Hans Biomed was 2024 14.82 % . It decreases by -69.01% lower compared to the previous year.

The Hans Biomed FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
73.77 KRW
Jan 1, 2019
-78.89 KRW
Jan 1, 2020
7.26 KRW
Jan 1, 2021
106.82 KRW
Jan 1, 2022
-134.31 KRW
Jan 1, 2023
25.17 KRW
Jan 1, 2024
14.82 KRW
Jan 1, 2025
4.59 KRW
The Hans Biomed FCF Conversion history
YEARFCF ConversionYoY
4.59 %-69.01%
14.82 %-41.11%
25.17 %-118.74%
-134.31 %-225.73%
106.82 %+1,371.54%
7.26 %-109.20%
-78.89 %-206.95%
73.77 %-177.51%
-95.18 %-56.10%
-216.83 %+308.58%
-53.07 %-82.03%
-295.30 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hans Biomed Stock analysis

What does Hans Biomed do? Hans Biomed Corp manufactures and sells graft material and silicon products under brand names SureDerm, BellaGen, and GPS for skin-implant materials used in burn treatment and skin graft. The company offers bone-implant materials including allogeneic bones, xenogenous bones, and synthetic bones under SureFuse, ExFuse, and SureOss for dentistry and orthopedic applications. Silicone products such as BellaGel and Scar Clinic are utilized for scar treatment and breast implants. The firm also provides hair transplanters as part of its product portfolio. Skin-implant materials under SureDerm, BellaGen, and GPS are purchased by medical facilities for burn treatment and skin graft procedures. Bone-implant materials under SureFuse, ExFuse, and SureOss are bought by dental and orthopedic clinics for various surgical needs. Silicone products BellaGel and Scar Clinic are acquired by healthcare providers for scar management and breast implant surgeries. Hair transplanters are sold to medical institutions requiring such equipment. The company's primary revenue streams come from the sale of skin-implant materials, bone-implant materials, and silicone products across medical, dental, and orthopedic sectors. Medical facilities, dental clinics, and orthopedic practices represent key customer segments. Brand names SureDerm, BellaGen, GPS, SureFuse, ExFuse, SureOss, BellaGel, and Scar Clinic drive product differentiation and market positioning in the healthcare industry. Hans Biomed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hans Biomed stock

FCF Conversion Rate (FCF/EBITDA) of Hans Biomed is 4.59 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Hans Biomed changed from 14.82 % to 4.59 %, representing a -69.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Hans Biomed since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Hans Biomed with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Hans Biomed

All Key Metrics — Hans Biomed